Climb Bio, Inc. (CLYM) · Aug 14, 2026 · Other events

CLYM116 hits Phase 2 on schedule—but brings no patient data

In line — First patient dosed in Q3 2026, as previously expected

Climb Bio’s partner dosed the first IgA nephropathy patient in China, confirming the Q3 plan but adding no efficacy or safety evidence.

The milestone landed inside the existing timeline. Climb Bio had already indicated that Mabworks expected to begin dosing IgA nephropathy patients in the Phase 2 portion of the study during the third quarter of 2026. The August 13 announcement therefore confirms execution rather than delivering a timing surprise.

The filing confirms trial advancement, not clinical success. Beijing Mabworks dosed the first patient in a China Phase 2 IgA nephropathy trial conducted with Climb Bio. 〔0〕 There are no patient efficacy results, safety findings, enrollment numbers, or revised development timelines in this 8-K.

Net: an execution confirmation, not a new value inflection. Because the direction and timing were already broadly expected, the filing is best scored In line: it removes some execution uncertainty around CLYM116 but does not yet change the clinical evidence base or establish that the drug works in IgA nephropathy.

Original filing on SEC EDGAR

More Climb Bio, Inc. news

CLYM116 hits Phase 2 on schedule—but brings no patient data | CLYM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.